Long bone formation is a complex process that requires precise
transcriptional control of gene expression programs in mesenchymal progenitor
cells. Histone deacetylases (Hdacs) coordinate chromatin structure and gene
expression by enzymatically removing acetyl groups from histones and other
proteins. Hdac inhibitors are used clinically to manage mood disorders, cancers
and other conditions, but are teratogenic to the developing skeleton and
increase fracture risk in adults. In this study, the functions of Hdac3, one of
the enzymes blocked by current Hdac inhibitor therapies, in skeletal mesenchymal
progenitor cells were determined. Homozygous deletion of Hdac3 in
Prrx1-expressing cells prevented limb lengthening, altered pathways associated
with endochondral and intramembranous bone development, caused perinatal
lethality, and slowed chondrocyte and osteoblast differentiation in vitro.
Transcriptomic analysis revealed that Hdac3 regulates vastly different pathways
in mesenchymal cells expressing the Prrx1-Cre driver than those expressing the
Col2-CreERT driver. Notably, Fgf21 was elevated in Hdac3-CKOPrrx1
limbs as well as in chondrogenic cells exposed to Hdac3 inhibitors. Elevated
expression of Mmp3 and Mmp10 transcripts was also observed. In conclusion, Hdac3
regulates distinct pathways in mesenchymal cell populations and is required for
mesenchymal progenitor cell differentiation and long bone development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.